Imagion Biosystems Ltd (IBX) - Total Assets
Based on the latest financial reports, Imagion Biosystems Ltd (IBX) holds total assets worth AU$2.04 Million AUD (≈ $1.45 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Imagion Biosystems Ltd - Total Assets Trend (2014–2025)
This chart illustrates how Imagion Biosystems Ltd's total assets have evolved over time, based on quarterly financial data. Also see IBX company net worth for the company's overall valuation and market capitalisation.
Imagion Biosystems Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Imagion Biosystems Ltd's total assets of AU$2.04 Million consist of 99.6% current assets and 0.4% non-current assets. Review IBX current and long-term liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 90.4% |
| Accounts Receivable | AU$34.20K | 1.7% |
| Inventory | AU$0.00 | 0.0% |
| Property, Plant & Equipment | AU$8.49K | 0.4% |
| Intangible Assets | AU$0.00 | 0.0% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2014–2025)
This chart illustrates how Imagion Biosystems Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See IBX live share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Imagion Biosystems Ltd's current assets represent 99.6% of total assets in 2025, an increase from 48.0% in 2014.
- Cash Position: Cash and equivalents constituted 90.4% of total assets in 2025, up from 48.0% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2014.
- Asset Diversification: The largest asset category is accounts receivable at 1.7% of total assets.
Imagion Biosystems Ltd Competitors by Total Assets
Key competitors of Imagion Biosystems Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
GeneDx Holdings Corp.
NASDAQ:WGS
|
USA | $481.49 Million |
|
Shanghai Runda Med Tech Co
SHG:603108
|
China | CN¥13.79 Billion |
|
Shanghai Rendu Biotechnology Co. Ltd. A
SHG:688193
|
China | CN¥984.02 Million |
|
DIVA Laboratories Ltd
TWO:4153
|
Taiwan | NT$1.38 Billion |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩131.23 Billion |
|
RHYTHM Biosciences Ltd
AU:RHY
|
Australia | AU$3.10 Million |
|
Check-Cap Ltd
F:7CC
|
Germany | €7.49 Million |
|
Avricore Health Inc
V:AVCR
|
Canada | CA$584.37K |
Imagion Biosystems Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.48 | 0.55 | 14.91 |
| Quick Ratio | 0.48 | 0.55 | 14.84 |
| Cash Ratio | 0.00 | 0.00 | 14.65 |
| Working Capital | AU$-2.17 Million | AU$-2.30 Million | AU$12.53 Million |
Imagion Biosystems Ltd - Advanced Valuation Insights
This section examines the relationship between Imagion Biosystems Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.84 |
| Latest Market Cap to Assets Ratio | 1.36 |
| Asset Growth Rate (YoY) | -27.1% |
| Total Assets | AU$2.04 Million |
| Market Capitalization | $2.78 Million USD |
Valuation Analysis
Above Book Valuation: The market values Imagion Biosystems Ltd's assets above their book value (1.36x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Imagion Biosystems Ltd's assets decreased by 27.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Imagion Biosystems Ltd (2014–2025)
The table below shows the annual total assets of Imagion Biosystems Ltd from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | AU$2.04 Million ≈ $1.45 Million |
-27.09% |
| 2024-12-31 | AU$2.80 Million ≈ $1.98 Million |
-38.87% |
| 2023-12-31 | AU$4.59 Million ≈ $3.25 Million |
-54.03% |
| 2022-12-31 | AU$9.98 Million ≈ $7.06 Million |
-29.33% |
| 2021-12-31 | AU$14.12 Million ≈ $9.99 Million |
-0.03% |
| 2020-12-31 | AU$14.12 Million ≈ $9.99 Million |
+189.79% |
| 2019-12-31 | AU$4.87 Million ≈ $3.45 Million |
-6.08% |
| 2018-12-31 | AU$5.19 Million ≈ $3.67 Million |
-32.11% |
| 2017-12-31 | AU$7.64 Million ≈ $5.41 Million |
-37.07% |
| 2016-12-31 | AU$12.14 Million ≈ $8.59 Million |
+1440.45% |
| 2015-12-31 | AU$788.19K ≈ $557.69K |
+132.84% |
| 2014-12-31 | AU$338.51K ≈ $239.52K |
-- |
About Imagion Biosystems Ltd
Imagion Biosystems Limited operates as a medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases in Australia. The company is involved in nanotechnology; biotechnology; medical imaging using magnetic resonance; and cancer diagnostics businesses. It develops MagSense, which is in Phase 2 for the treatment of HER2 breast cancers, as well as advancing th… Read more